







Q

Home ► All Journals ► Medicine ► Leukemia & Lymphoma ► List of Issues ► Volume 56, Issue 4 ► Imatinib mesylate lacks efficacy in rela

Leukemia & Lymphoma >

Volume 56, 2015 - <u>Issue 4</u>

245 3 Views CrossRef citations to date O Altmetric

Original Article: Clinical

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

Eric Jacobsen ☑, Olga Pozdnyakova, Robert Redd, David C. Fisher, David M. Dorfman, Paola Dal Cin, …show all

Pages 993-998 | Received 03 Jun 2014, Accepted 30 Jun 2014, Accepted author version posted online: 11 Jul 2014, Published online: 20 Aug 2014





- Full Article
- Figures & data
- References
- Supplemental
- **66** Citations
- Metrics

- Reprints & Permissions
- Read this article



Abstract

Platelet derived growth factor- α (PDGFR- α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR- α expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1-PDGFR- α fusion and/or PDGFR- α amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis of PDGFR- α by immunohistochemistry and three of these patients' tumors expressed

PDGFR- α . Imatinib was not effective for the treatment of peripheral T cell lymphoma in
an unselected group of patients in which PDGFR- $lpha$ expression was not required for
study entry.
Keywords::
Lymphoma imatinib $PDGFR-\alpha$
Potential conflict of interest.

Potentiai conffict of interest:

<u>Disclosure</u> forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.



Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

Keep up to date

Register to receive personalised research and resources by email



Sign me up











Accessibility



Copyright © 2025 Informa UK Limited Privacy policy Cookies Terms & conditions



Registered in England & Wales No. 01072954 5 Howick Place | London | SW1P 1WG